SCHEMBL2337896

SCHEMBL2337896

[NH]S(=O)(=O)CCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 6/20 0.53
IDO1 P14902 1/20 0.50
CA1 P00915 3/20 0.46
LMNA P02545 2/20 0.46
CA12 O43570 1/20 0.46
CA7 P43166 1/20 0.46
CA13 Q8N1Q1 1/20 0.46
CA9 Q16790 2/20 0.45
MMP12 P39900 2/20 0.44
MMP13 P45452 2/20 0.44
MMP1 P03956 1/20 0.44
MMP7 P09237 1/20 0.44
MMP8 P22894 1/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
CASP1 P29466 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5700135 0.86 CA2 (0.56) CA2ALDH1A1KDM4EMAPT
SCHEMBL5700310 0.85 CA2 (0.50) CA2ALDH1A1MAPT
SCHEMBL302785 0.80 CA2 (0.69) CA2IDO1CA1LMNACA12
SCHEMBL293747 0.78 CA2 (0.55) CA2IDO1CA1LMNACA12
SCHEMBL8788953 0.77 CA2 (0.60) CA2IDO1CA1LMNACA12
SCHEMBL15695395 0.77 CA2 (0.50) CA2IDO1CA1LMNACA12
SCHEMBL11580921 0.77 CA2 (0.50) CA2CA1LMNACA9ALDH1A1
SCHEMBL14495267 0.76 CA2 (0.77) CA2IDO1CA1LMNACA12
SCHEMBL248501 0.76 CA2 (0.53) CA2IDO1CA1LMNACA12
SCHEMBL1644097 0.76 CA2 (0.70) CA2IDO1CA1LMNACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2361906-A1 Process for preparing rosuvastatin AstraZeneca UK Limited (GB) 2011-08-31 EP claimed
US-20080207903-A1 Chemical Process ASTRAZENECA UK LIMITED (GB) 2008-08-28 US claimed
EP-1871747-A2 PROCESS FOR PREPARING ROSUVASTATIN AstraZeneca UK Limited (GB) 2008-01-02 EP claimed
WO-2006067456-A2 PROCESS FOR PREPARING ROSUVASTATIN ASTRAZENECA UK LIMITED (GB) 2006-06-29 WO claimed
US-8034932-B2 Hydroxy-3-methylglutaryl/3-/ coenzyme A reductase inhibitor; anticholesterol agents;dyslipidemia; chemical intermediate for rosuvastatin ASTRAZENECA UK LIMITED (GB) 2011-10-11 US disclosed
EP-2361906-A1 Process for preparing rosuvastatin AstraZeneca UK Limited (GB) 2011-08-31 EP disclosed
US-20080207903-A1 Chemical Process ASTRAZENECA UK LIMITED (GB) 2008-08-28 US disclosed
US-7223755-B2 Hydroxymorpholinone derivative and medicinal use thereof SENJU PHARMACEUTICAL CO., LTD. (JP) 2007-05-29 US disclosed
EP-1084710-B1 ADENOSINE A1 ANTAGONISTS FOR MALE STERILITY ASTELLAS PHARMA INC (JP) 2006-10-18 EP disclosed
US-7071359-B1 Neuropathy improvers containing nitrogenous compounds as the active ingredient TEIJIN LIMITED (JP) 2006-07-04 US disclosed
EP-1146037-B1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AMINO ALCOHOLS NIPPON SODA CO (JP) 2006-06-21 EP disclosed
EP-1201235-B1 NEUROPATHY IMPROVERS CONTAINING NITROGENOUS COMPOUNDS AS THE ACTIVE INGREDIENT TEIJIN LTD (JP) 2005-10-12 EP disclosed
US-5594003-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-14 US disclosed
US-5591762-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-07 US disclosed
EP-0644762-A1 PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-03-29 EP disclosed
WO-1993025205-A1 PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-12-23 WO disclosed
EP-0502314-A1 Benzimidazol, medicaments containing them and process for their preparation Dr. Karl Thomae GmbH (DE) 1992-09-09 EP disclosed
CN-1062143-A Condensed heterocyclic compouds and preparation thereof and application TAKADA CHEMIEAL IND LTD (JP) 1992-06-24 CN disclosed
US-4275148-A THIO SUBSTITUTED PYRAZOLINES AS MAGENTA COUPLERS KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1981-06-23 US disclosed
US-4217410-A CYAN DYE COUPLER, PHOSPHATE SOLVENTS FUJI PHOTO FILM CO., LTD. (JP) 1980-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207903-A1 Chemical Process CYP2C9, CYP2B6, CYP7A1 CA2 829/4885IDO1 4565/4885CA1 1506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.